JCR Pharmaceuticals Co., Ltd. announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo®?, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease. The achievement of a predefined research milestone triggers a milestone payment to JCR. JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
800 JPY | -0.74% | -1.84% | -31.74% |
04-25 | JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024 | CI |
03-21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.74% | 651M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion